中文摘要：

先天免疫是宿主防御的第一道防線，并參與疼痛的發(fā)生機(jī)制。然而,，先天免疫系統(tǒng)如何與感覺神經(jīng)元相互作用以調(diào)控疼痛,，目前仍知之甚少。在此,，我們報(bào)道白細(xì)胞介素33（IL-33）引發(fā)痛覺過(guò)敏，這一過(guò)程需要浸潤(rùn)的巨噬細(xì)胞和中性粒細(xì)胞分泌趨化因子(C-C基序)配體2（CCL2），并激活感覺神經(jīng)元中的瞬時(shí)受體電位香草酸1（TRPV1）和瞬時(shí)受體電位褪黑素8（TRPM8）通道,。阻斷CCL2受體（CCR2）可減輕IL-33誘導(dǎo)的和弗氏佐劑（CFA）誘導(dǎo)的熱痛覺過(guò)敏；阻斷TRPV1和TRPM8則分別減輕IL-33誘導(dǎo)的機(jī)械性痛覺敏感性,、熱覺敏感性以及冷痛覺異常,。此外，巨噬細(xì)胞的耗竭（荷蘭Liposoma巨噬細(xì)胞清除劑）減少了IL-33誘導(dǎo)的疼痛,、CCL2的表達(dá)及后爪皮膚中腫瘤發(fā)生抑制因子2（ST2）的抑制,；抑制CCR2可防止巨噬細(xì)胞和中性粒細(xì)胞的招募。我們的發(fā)現(xiàn)揭示了一個(gè)未被認(rèn)識(shí)的神經(jīng)免疫串?dāng)_：浸潤(rùn)免疫細(xì)胞中的IL-33-CCL2信號(hào)與感覺神經(jīng)元中的TRPV1/TRPM8相互作用,，共同促進(jìn)疼痛狀態(tài),。

英文摘要：

Innate immunity is the first line of host defense and contributes to pain. However, how innate immune system interacts with sensory neurons to govern pain remains poorly understood. Here, we report that interleukin 33(IL-33) initiates pain hypersensitivity that requires chemokine (C-C motif) ligand 2 (CCL2) secretion from infiltrated macrophages and neutrophils and activation of transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential melastatin 8 (TRPM8) channels in sensory neurons. Blocking CCL2 receptor (CCR2) attenuates IL-33- induced and Complete Freund’s adjuvant (CFA)-induced thermal hyperalgesia and blocking TRPV1 and TRPM8 attenuates IL-33-induced mechanical and thermal hypersensitivity and cold allodynia respectively. Furthermore, depletion of macrophages reduces IL-33-induced pain and expression of CCL2 and suppression of tumorigenicity 2 (ST2) in hindpaw skin and inhibition of CCR2 prevents recruitment of macrophages and neutrophils. Our findings reveal an unrecognized neuroimmune crosstalk of IL-33-CCL2 signaling from infiltrated immune cells with TRPV1/TRPM8 in sensory neurons to facilitate pain states.

論文信息：

論文題目：IL-33/ST2 drives inflammatory pain via CCL2 signaling and activation of TRPV1 and TRPM8

期刊名稱：Nature Communications

時(shí)間期卷：8, Article number: 724 (2025)

在線時(shí)間：2025年5月10日

DOI：doi.org/10.1038/s42003-025-08119-3

產(chǎn)品信息：

貨號(hào)：CP-005-005

規(guī)格：5ml+5ml

品牌：Liposoma

產(chǎn)地：荷蘭

名稱：Clodronate Liposomes and Control Liposomes

辦事處：Target Technology（靶點(diǎn)科技）

注射方式：腹腔注射

劑量和頻率：200ul/次，每天一次,，連續(xù)注射兩次

氯膦酸鹽二鈉脂質(zhì)體清除單核巨噬細(xì)胞,，在疼痛模型中單核巨噬細(xì)胞功能研究,，荷蘭Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes見刊于Nature Communications：IL-33/ST2通過(guò)CCL2信號(hào)傳導(dǎo)和TRPV1及TRPM8的激活推動(dòng)炎癥性疼痛

Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體的材料和方法：

Drug treatment in pain models

In the pre-treatment study, ST2 neutralizing antibody (0.5?μg/10?μL, MAB10041, R&D), CCR2 antagonist (INCB3344, 0.5?μg/10?μL, Apebio) or PBS was intraplanatarly delivered 30?min before IL-33 injection. Then mechanical PWT or thermal PWL was measured at 1, 2, and 4?h after IL-33 injection. For the post-treatment study, CFA model was set up and INCB3344 was intraplantarly injected at day 3 after CFA injection, then PWL was measured. For the macrophage depletion experiment, clondronate (200?μL, CP-005-005, Liposoma) was intraperitoneal injected once a day for two days, then IL-33 was intraplantarly injected. PWT and PWL were measured at 1, 2, and 4?h after IL-33 application.